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data on the general population. Specific examples of large systematic reviews con-
ducted for estimating food safety accounting for population variability and inter-
actions between food contaminants and drugs are also presented. Details on the 
model-based meta-analyses of such safety data are described and discussed for the 
purpose of regulator’s decision making. Systematic reviews have been to the context 
of food and nutritional epidemiology requiring more stringent quality assessment 
and more advanced management of variability. This resulted in a Bayesian random 
effect model accounting for population variability. Metabolic interactions between 
food and drugs were evidenced and variability metrics could be explicated in terms of 
“uncertainty factors” to be used by the food regulators to assess safety limits for food 
ingredients, contaminants or drugs and their combined use. Food regulator in EU is 
aligning and even sometimes anticipating drug regulators in terms of evidence-based 
safety assessment in the real life. Common tools for model-based evidence synthesis 
can be applied to quantify safety signals and interaction in the general population.
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Objectives: Cost-effectiveness analyses (CEA) have become widely used in several 
pathologies. Currently, new CEA studies comparing active vs control treatment have 
been incorporated each year. For this reason, the combination of CEA studies could 
give a more consistent and accurate estimate of an intervention’s efficiency than 
one study alone. The aim of study was to develop a new method to do compara-
tive efficiency research (COMER) based in individual patient data. MethOds: After, 
adjusted the marginal distribution and copula distribution of a hypothetical cohort, 
we stated the parameters and distribution estimated like our unknown theoretical 
distribution. We conducted an iterative analysis of a random Frank Copula distribu-
tion with a different range of sample size. We performed a comparison between 
samples and theoretical distribution in terms of incremental cost-effectiveness ratio 
(ICER), incremental monetary benefit(IMB) fixed a threshold (k= 20.000 monetary 
units) and goodness of fit for Frank copula, assuming a tolerance. Results: The 
Theoretical distribution fixed, showed a cost of 604.34 monetary units for active and 
516.12 monetary units for control, and a utilities of 0.529 for active and 0.492 for 
control. ICER for theoretical cohort was 2,380 monetary units per quality-adjusted 
life year gained and IMB was 653. With a tolerance of 500 monetary units for ICER 
and 50 monetary units for IMB, only 15.52% of simulations were near the theoretical 
ICER and only 6.12% of IMB. The amount of individual patients simulated was more 
than 500 patients per treatment to fit Frank Copula. cOnclusiOns: Preliminary 
results showed that COMER based in individual patients’ data could allow decision 
maker to know real add-value of a new intervention.
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Benefits of diagnostics tests generally centre on test accuracy measures. However, 
additional benefits of diagnostics may include: reduced laboratory time, reduced time 
to results and increases in the capacity of a laboratory to deliver more tests. New tech-
nological developments, such as high throughput sequencing (HTS) are challenging the 
current methods used in establishing the case for the introduction into clinical practice 
terms of economic impact. This is evident in the case study developed here examining 
BRCA1/2 genetic testing in providing information on the risk of development of breast 
cancer. Current BRCA1/2 testing technologies are limited by long (up to one-year) turna-
round times, which together with limited resources to increase the volume of tests 
and associated genetic counselling, has driven the use of a ‘risk threshold’ to target 
women eligible for testing. HTS offers the opportunity of decreased turnaround time 
and increased volume of BRCA1/2 tests, which will impact on the benefits and costs 
associated with the diagnostic service. Systematic reviews have identified Markov-type 
models as the dominant modeling methodology for the assessment of genetic testing. 
We propose that discrete event simulation (DES) is the appropriate model type to quan-
tify the economic impact of HTS BRCA1/2 testing as it allows evaluation of the impact 
of capacity constraints and increased turnaround time on the costs and benefits of 
this new diagnostic technology. Importantly, DES also allows for the assessment of 
structural uncertainty by considering changes in patient pathways when using a new 
diagnostic technology. While DES may be the most appropriate modeling methodology 
in assessing the economic impact of novel genetic tests; typically the type of data and 
information required to popuate these models in lacking. We conclude by highlighting 
the type of data required to both population appropriate models and to adequately 
assess the economic impact of these novel genetic tests.
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In this paper, we critically evaulated analytical design of health technology assess-
ment methodologies, particularly related to sensitivity analyses and willingness-
to-pay thresholds. To this end, we have used two studies: the first one analyzing 
cost-effectiveness of a human papillomavirus vaccination of boys at age 12 against 
oropharyngeal carcinoma and anogenital warts and the second one examining 
cost-effectiveness of a universal programme of vaccinating children against pneu-
mococcal disease. We have shown – as expected – that the impact of variation of 
parameters can be substantial, however, outcomes of sensitivity analyses are often 
understated both by marketing authorization holders and authorities. Few would 
of a biopharmaceutical company. An approach based on real options valuation 
model was proposed to support investment and market decisions and to predict the 
potential net present value (NPV) of a drug. The conceptual structure of the model 
was face-validated by health economic and valuation experts. Results: A deci-
sion-tree based valuation method, populated partially by information from health 
economic tools, was adopted to analyse and clearly communicate R&D investment 
opportunities, to capture management flexibility and to improve strategic thinking. 
A feedback loop can be built into the model to analyse resiliency to assumption 
changes. In early phases, headroom and multi-criteria decision analyses indicate 
the likelihood of an investment being cost-effective. Phase I and II trials provide 
early evidence on drug efficacy and tolerability and initial cost estimates. Based 
on value of information, cost-effectiveness and budget impact models, only drugs 
deemed to meet authority requirements would be selected. Market intelligence 
and uncertainties and clinical success probability further enable identification of 
the optimal portfolio containing drug candidates that maximize NPV for given risk 
levels. cOnclusiOns: Health economic methods are commonly applied during 
late stage development, but if implemented alongside capital investment tools from 
earliest R&D stages they could increase the likelihood of selecting the right products 
to compose an effective investment portfolio.
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Cancer treatment effectiveness is often quantified by analyzing time from treat-
ment initiation to the occurrence of a particular event. Very commonly studies 
report data on overall survival (OS), where the event is death from any cause, and on 
progression-free survival (PFS), where the event is death from any cause or disease 
progression, whichever occurred first. Both OS and PFS can inform decision making. 
Separate meta-analyses of OS and of PFS data ignore the correlation between the 
outcomes. We introduce a method for the joint meta-analysis of OS and PFS that is 
based on a tri-state transition model with time-varying hazard rates modeled with 
fractional polynomials. In English, we assume that, at any time, patients can be in 
one of three health states: “alive but not progressed”, “alive and progressed”, and 
“dead”. PFS corresponds to time spent in the first state, and OS to time spent in the 
two alive states. The proposed approach allows the joint network meta-analysis 
of OS and PFS, relaxes the proportional hazards assumption, extends to a network 
of more than two treatments, and simplifies the parameterization of decision and 
cost-effectiveness analyses. The data needed to run these analyses can be extracted 
directly from published survival curves. We demonstrate use by applying the meth-
odology to a network of trials for the treatment of non-small cell lung cancer.
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bAckgROund: The global economic crisis imposes severe restrictions on budgets 
allocated to health care. Innovative technologies in medicine may improve patient 
outcomes but such improvements come at a substantial cost, thus limiting the num-
ber of patients that may benefit from them. According to current cost-effectiveness 
analyses (CEA), most innovative interventions are associated with a higher efficacy 
and higher costs compared with the standard of care. These analyses do not account 
for the budget impact associated with implementing the interventions on all eligible 
patients. Even when a new intervention is highly cost-effective, health care systems 
may not be able to adopt it due to substantial budgetary impacts. Implementing a 
substantially lower-cost intervention to a substantially wider population, accept-
ing inferior per-patient outcomes, may improve overall health outcomes under a 
restricted budget. Objectives: Develop an innovative health technology assess-
ment (HTA) model that combines CEA and budget-impact analyses, thus enabling to 
compare the impact of intervention alternatives on the entire intended use popula-
tion, under a pre-specified budget constraint. MethOds: We identified the follow-
ing steps to be included in the model formulation: 1) Define the intended use and the 
target population. 2) Define two or more interventions, one of them at higher cost 
and better per-patient outcome, and the second with lower cost and inferior per-
patient outcome. 3) Forecast the diffusion of the alternatives into the entire intended 
use population, under a pre-defined budget, in order to estimate the treated and 
untreated populations. 4) Calculate the clinical impact of each alternative on the 
treated population. 5) Calculate the clinical impact of no therapy on the untreated 
population 6) Compare the aggregated clinical impact of each alternative on the 
entire intended use population – both treated and untreated. Using the proposed 
population-based model may result in improved health care outcomes, especially 
in times of economic downturn and austerity.
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Evidence-based medicine has emerged as the bottom line of Health Technology 
Assessments for drug evaluations. Over the last decade, evidence-based assessment 
of food and nutritional products has accelerated. Specific quantitative tools to syn-
thetize evidence have been increasingly developed, and used for decision support. 
This work aims at highlighting the critical role of systematic reviews and model-based 
evidence synthesis in the field of food sciences and nutrition, especially with the view 
of safety assessment. To first set the scene of food assessment in Europe, the latest 
Guidelines on Systematic Reviews published by the European Food Safety Authority 
(EFSA) (EFSA, 2010) are described with the approach on how to handle observational 
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and matched for age, gender and geographic location. The index date was defined 
as the date of the first AD diagnosis or the first script for AD medication whichever 
comes first. Prevalence of diseases and treatment exposures in the years preceding 
the index date were analyzed according to the occurrence of diseases (ICD-9 codes) 
and medication utilization (AHFS codification) between AD patients and the control 
group. Results: Data were obtained for a random sample of 34,086 AD patients 
(mean age of 78.5 years [SD= 8.0], 65.2% females). A higher proportion of patients 
had a diagnosis of organic psychotic conditions (49.6% vs. 9.2%, p< 0.001), other 
psychoses (21.9% vs. 8.6%, p< 0.001) and neurotic disorders, personality disorders 
and other nonpsychotic mental disorders (69.1% vs. 55.4%, p< 0.001) in the AD group 
compared to the control group. Furthermore, a greater number of patients used psy-
chotropic drugs (53.5% vs. 35.9%, p< 0.001) and anxiolytics, sedatives and hypnotics 
(70.3% vs. 65.9%, p< 0.001) in the AD group than in the control group. cOnclusiOns: 
Comorbidities’ frequency was higher in AD patients for several diseases and treat-
ments, particularly for mental disorders-related diagnoses and medications.
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Objectives: To estimate the efficacy of fingolimod versus placebo on confirmed 
disability progression (CDP) and on time to severe disability health states in 
patients with relapsing–remitting multiple sclerosis (RRMS) failing prior treat-
ment. MethOds: Patients failing prior treatment were defined as: 1) ≥ 1 relapse 
in the previous year and either ≥ 1 gadolinium-enhancing T1 lesion or a T2 lesion 
count ≥ 9 at baseline, or 2) equal or more relapses in the year prior to baseline 
compared with the previous year. Hazard ratios (HR) for 3-month and 6-month CDP, 
measured using Expanded Disability Status Scale (EDSS) scores, were estimated 
using Cox proportional hazards models. Both per-protocol definitions of CDP and 
revised definitions used in other trials were analysed. Time from EDSS score 0 to 
scores of 4 or 6 and to conversion to secondary progressive MS (SPMS) were esti-
mated by fitting a multi-state Markov Transition model to individual patient data 
from the pooled FREEDOMS placebo groups (HRs accounted for treatment effects) 
and the London Ontario cohort (SPMS and RRMS–SPMS transitions). Results: 
Using both definitions of treatment failure, fingolimod reduced the risk of 3-month 
CDP (per-protocol) by 35% (definition 1: HR: 0.65; p< 0.05) and 34% (definition 2: 
HR: 0.66; p< 0.05) versus placebo. The corresponding HRs for 6-month CDP were 
0.61 (p= 0.06) and 0.60 (p< 0.05). HRs were generally lower using the revised CDP 
definition. The Markov Transition model, assuming a 40% reduction, estimated 
that fingolimod delays the median time to EDSS 4 (2.2 years, 61% increase), EDSS 
6 (3.3 years, 52% increase) and SPMS (4.5 years, 62% increase) compared with pla-
cebo. cOnclusiOns: Fingolimod is highly efficacious in delaying CDP in patients 
failing prior treatment, and our modeling approach suggests that this translates 
into a meaningful delay in time to severe disability health states.
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Objectives: As the number of available disease-modifying therapies (DMT) for 
relapsing-remitting multiple sclerosis (RRMS) expands, consideration of all evidence 
on comparative efficacy of newer second generation therapies with established 
first generation therapies is required to inform clinical care and health policy. This 
network meta-analysis (NMA) estimates the relative efficacy of DMT in reducing 
relapses and slowing short-term progression of disability in RRMS. MethOds: A 
systematic review of RCTs of interferon-beta, glatiramer acetate (first generation 
DMTs), natalizumab, alemtuzumab, fingolimod, teriflunomide, laquinimod, and 
BG-12 (second generation DMTs) compared with each other or with placebo for the 
treatment of RRMS, identified 20 eligible RCTs (n= 14610). A random-effects NMA 
model was used to calculate relative annualized relapse rate (ARR) and hazard 
ratio (HR) of short-term disability progression. Results: Statistically significant 
reductions in ARR versus placebo, between 24% - 69% for second generation DMTs 
and 16% - 33% for first generation DMTs were found. Alemtuzumab, natalizumab, 
fingolimod, and BG-12 were significantly more efficacious than other DMTs in 
reducing ARR. There was greater uncertainty associated with DMT efficacy in reduc-
ing short-term disability progression. Significant improvements over placebo in 
reducing short-term disability progression were restricted to second generation 
DMTs alemtuzumab, natalizumab, fingolimod, laquinimod, BG-12, and terifluno-
mide 14mg (HR 0.27 - 0.54). No statistically significant improvements in short-term 
disability progression were exhibited by first generation DMTs and teriflunomide 
7mg. cOnclusiOns: The growing number of innovative second generation DMTs 
offers the potential of therapeutic advances in reducing relapse rates in RRMS, with 
less certain benefits on short-term disability progression. Despite these potential 
advantages, the relative position of second generation DMTs on the RRMS treatment 
landscape remains to be defined, due to potentially serious side effects, limited 
long-term safety data and their high cost.
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disagree that innovation in health care is worthwhile; the tremendous technological 
success in pharmacological treatment of HIV patients is a case in point. On the other 
hand, a relatively large number of “me-too” entries in the pharmaceutical market 
and the diminishing productivity of R&D sector call for robust methodologies, which 
could distinguish high-value, breakthrough products. Sensitivity analyses of cost-
effectiveness studies should be made pivotal in decision-making process in order 
to ensure efficient diffusion of innovation.
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The introduction of the risk management plan (RMP) has ensured greater proactivity 
to the pharmacovigilance and post-authorisation benefit risk assessment of human 
medicines. An RMP may include risk minimisation measures (RMM), public health 
interventions intended to prevent the occurrence, or reduce the impact of adverse 
drug reactions associated with the exposure to a drug. The new EU legislation on 
pharmacovigilance explicitly requires the active monitoring of the outcome of RMM, 
placing obligations on regulators and industry for this purpose. In this respect, the 
European Medicines Agency’s good pharmacovigilance practices module dedicated 
to the practical implementation of the legislation on the evaluation of the effective-
ness of RMM foresees a dual evidence approach. This approach builds on the assess-
ment of two distinct levels of evidence: the actual implementation of the RMM, and 
the attainment of its final objective(s). The approach requires research encompass-
ing analysis of implementation (process indicators), and traditional epidemiological 
research addressing the attainment (final outcome indicators) of RMM. Surveys 
are usually involved in the assessment of process indicators, in particular when 
RMM imply the provision of educational information to health care professionals 
(HCP) and the surveys are intended to measure what the HCP have learned. This 
paper aims to conceptualise the construction of surveys designed for the analysis of 
implementation of RMM. Such surveys should be developed following the principles 
of content validation. This requires a body of relevant questions (items), the sample 
population to which it will be administered, and a test plan. The test plan includes 
the type of items to be used, the number of items, the length of administration, 
how it is to be administered, and how it is to be scored and analysed in terms of 
item difficulty and discrimination. The paper concludes with a checklist to assist 
stakeholders in designing surveys for RMM assessment purposes.
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Objectives: To summarize literature on the burden of epilepsy in tuberous sclero-
sis complex (TSC); TSC is a genetic disease characterized by behavioral disorders, 
benign tumors in multiple organs, and neurological manifestations including epi-
lepsy. MethOds: A systematic search of keywords for TSC and burden of illness 
was conducted in MEDLINE- and EMBASE-indexed publications from 5/2000-1/2013, 
and non-indexed materials. Results: In total, 83 articles on TSC-associated epi-
lepsy were included. Up to 93% of TSC patients have epilepsy, with severe forms 
more common than in non-TSC epilepsy patients (infantile spasms, 35-57% vs. 9%; 
generalized tonic-clonic or grand mal seizures, 37% vs. 7%; complex focal seizures, 
87% vs. 33%). Seizure onset is early (median age: 7 months, 82% by age 3). TSC2 
gene mutations and cortical tubers, common brain malformations in TSC, are risk 
factors for early onset and greater severity of seizures. TSC-epilepsy patients have 
significant disabilities, including high rates of autism spectrum disorders (13-30%) 
and cognitive impairment/delay (62-80%). Although data are not available on long-
term outcomes, early seizure control may reduce cognitive impairment and autism 
symptoms. Vigabatrin is a first-line treatment option for TSC-associated infantile 
spasms and focal seizures in infants, but poses a risk of serious retinal toxicity. 
Other anti-epileptic drugs are available as second-line options; most patients still 
require polytherapy, and 62% have refractory epilepsy that can necessitate surgery. 
With high rates of medication use, hospitalizations, and surgeries, TSC-epilepsy 
patients may consume substantial health care resources, particularly during the 
first 5 years post-diagnosis. Longitudinal trends in resource use, direct and indirect 
costs, and treatment patterns for TSC-epilepsy are largely absent from the litera-
ture. cOnclusiOns: TSC-epilepsy is common and may be severe, with presenta-
tion early in childhood and long-term morbidity. True disease burden to patients, 
caregivers, and payers remains unknown given substantial data gaps in longitudinal 
clinical outcomes, treatment patterns, and costs.
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Objectives: To identify potential determinants of Alzheimer’s disease (AD) by ana-
lyzing past medical history in terms of previous diseases or treatment exposures 
of patients with AD compared to patients without the disease, using the Quebec 
provincial drug reimbursement program database (RAMQ). MethOds: This ret-
rospective study included patients covered by the RAMQ who had at least one 
diagnosis of AD (ICD-9 code 3310) or have received at least one script for an AD 
medication (donepezil, rivastigmine, galantamine or memantine) from January, 1985 
to December, 2011. A control group of patients without AD was created on a 1:1 ratio 
